1. June 11, 2013
COTI-2 | A Potential Breakthrough
Therapy for Many Cancers

2. 2TSXV: COT
About COTI-2
Late preclinical
drug candidate
discovered using
CHEMSAS®
- the company’s proprietary,
artificial intelligence-based
drug discovery technology
2TSXV: COT

3. 3TSXV: COT
COTI-2 highlights
1
2
3
Potential breakthrough therapy for
many cancers
Active against many cancers with
mutations of the p53 gene
> 50% of all human cancers have a p53
mutation

4. 4TSXV: COT
Why p53 is important?
p53 is a tumour
suppressing
gene
A mutation of the p53 gene is the most common
mutation found in human cancer cells
If mutated, cancers
can develop & grow
without control

5. 5TSXV: COT
The future of cancer treatments
COTI-2 would
treat genetic
mutations
common in many
types of cancer
Most current treatments
are organ specific
(i.e. treatment for lung cancer,
colon cancer, etc.)
COTI-2 targets and
primarily destroys
tumor cells
By way of contrast,
traditional chemotherapy
kills growing & dividing
cells, cancer or healthy

6. 6TSXV: COT
COTI-2 development progress
Easily synthesized oral formulation with no
stability issues
Effective alone or in combination with approved
cancer drugs
In final two-species toxicity studies prior to FDA
filing in late 2013 enabling human trials

7. 7TSXV: COT
4 U.S. patents granted – strengthening COTI-2’s value
proposition
o Composition of matter protection to 2030
Patents pending in USA, Europe, Canada and Japan
Patent strategy preserves downstream patent filing
opportunities for potential extension of market
exclusivity
We own all intellectual property with no license
obligations
COTI-2 intellectual property overview

8. 8TSXV: COTTSXV: COT
Why license COTI-2?
Drug development is a long and expensive process
Our core competence is accelerating drug
discovery, not drug development
Recent preclinical oncology licensing deals
included:
o Upfront payments of approx. $5-$15 million
o Milestone payments between $120-$288 million
o Royalties on net sales

9. 9TSXV: COT
When used anywhere in this presentation, whether oral or written, the words potential,
expects, believes, anticipates, estimates and similar expressions are intended to identify
forward-looking statements. Forward-looking statements may include statements
addressing future financial and operating results of Critical Outcome Technologies Inc.
(COTI).
COTI bases these forward-looking statements on its current expectations about future
events. Such statements are subject to risks and uncertainties including, but not limited to,
the successful implementation of COTI’s strategic plans, the acceptance of new products,
the obsolescence of existing products, the resolution of potential patent issues,
competition, changes in economic conditions, and other risks described in COTI’s public
documents such as press releases and filings with the Toronto Stock Exchange and the
Ontario Securities Commission.
All forward-looking statements are qualified in their entirety by the cautionary statements
included in this document and such filings. These risks and uncertainties could cause actual
results to differ materially from results expressed or implied by forward-looking statements
contained in this presentation. These forward-looking statements speak only as of the date
of this presentation.
Disclaimer

10. COTI-2 | A Potential Breakthrough
Therapy for Many Cancers